Tailoring varenicline to individual needs (TVIN)

• Research type

  Research Study

• Full title

  Effects of a tailored dose of varenicline on post-quitting urges to smoke

• IRAS ID

  63246

• Contact name

  Al-Rehan Abdul Aziz Dhanji

• Sponsor organisation

  Barts and the London School of Medicine and Dentistry, Queen Mary University of London

• Eudract number

  2010-022335-11

• Clinicaltrials.gov Identifier

  NCT01206010

• Research summary

  Varenicline (also known as Champix) is an effective treatment for stopping smoking. There are differences between smokers in their reactions to varenicline. During use prior to stopping smoking some people report that their enjoyment for cigarettes is reduced and/or they experience nausea (feeling sick) while others are not affected by the tablet. It is likely that the standard dose given to smokers leaves many people under-dosed. This is a proposal for a study that looks at whether increasing the dose of varenicline in patients who do not have any reaction to the drug in the first week of use can improve how helpful the drug is in helping people to stop smoking.

• REC name

  London - Harrow Research Ethics Committee

• REC reference

  10/H0709/84

• Date of REC Opinion

  17 Dec 2010

• REC opinion

  Further Information Favourable Opinion